BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2010; 2(4): 139-142 [PMID: 21160985 DOI: 10.4254/wjh.v2.i4.139]
URL: https://www.wjgnet.com/1948-5182/full/v2/i4/139.htm
Number Citing Articles
Venessa Pattullo, Mark W Douglas, Jacob George. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?Expert Review of Gastroenterology & Hepatology 2011; 5(2): 265 doi: 10.1586/egh.11.12
Dan-Qin Sun, Sheng-Jie Wu, Wen-Yue Liu, Qian-Di Lu, Gui-Qi Zhu, Ke-Qing Shi, Martin Braddock, Dan Song, Ming-Hua Zheng. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver diseaseExpert Opinion on Therapeutic Targets 2016; 20(3): 375 doi: 10.1517/14728222.2016.1096930
Michael S Kostapanos, Anastazia Kei, Moses S Elisaf. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseWorld Journal of Hepatology 2013; 5(9): 470-478 doi: 10.4254/wjh.v5.i9.470
Juan P Arab, Roberto Candia, Rodrigo Zapata, Cristián Muñoz, Juan P Arancibia, Jaime Poniachik, Alejandro Soza, Francisco Fuster, Javier Brahm, Edgar Sanhueza, Jorge Contreras, M Carolina Cuellar, Marco Arrese, Arnoldo Riquelme. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice reviewWorld Journal of Gastroenterology 2014; 20(34): 12182-12201 doi: 10.3748/wjg.v20.i34.12182
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Georgia Deretzi. Nonalcoholic Fatty Liver DiseaseJournal of Clinical Gastroenterology 2012; 46(4): 272 doi: 10.1097/MCG.0b013e31824587e0
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitusTherapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
Theodosios D. Filippatos. A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin CombinationCardiovascular Drugs and Therapy 2012; 26(3): 245 doi: 10.1007/s10557-012-6394-0
Klementina Fon Tacer, Damjana Rozman. Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid DeregulationJournal of Lipids 2011; 2011: 1 doi: 10.1155/2011/783976
Theodosios D Filippatos, Moses S Elisaf. Role of ezetimibe in non-alcoholic fatty liver diseaseWorld Journal of Hepatology 2011; 3(10): 265-267 doi: 10.4254/wjh.v3.i10.265
Stergios A Polyzos, Jannis Kountouras, Efthimia Zafeiriadou, Kalliopi Patsiaoura, Evangelia Katsiki, Georgia Deretzi, Christos Zavos, Georgios Tsarouchas, Pantelitsa Rakitzi, Aristidis Slavakis. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver diseaseJournal of the Renin-Angiotensin-Aldosterone System 2011; 12(4): 498 doi: 10.1177/1470320311402110
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos, Moses S. Elisaf. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular diseaseMetabolism 2012; 61(7): 906 doi: 10.1016/j.metabol.2011.12.002
Niki Katsiki, Moses Elisaf. Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney diseaseCurrent Medical Research and Opinion 2011; 27(8): 1669 doi: 10.1185/03007995.2011.596410
Peng Cheng, Sheng Sheng Yang, Xian Gui Hu, Xu Yu Zhou, Yi Jie Zhang, Gang Jin, Ying Qi Zhou. Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alphaFEBS Letters 2011; 585(21): 3403 doi: 10.1016/j.febslet.2011.09.043
A. N. Mavrogiannaki, I. N. Migdalis. Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer DataInternational Journal of Endocrinology 2013; 2013: 1 doi: 10.1155/2013/450639
Wu-wen Feng, Shuang-yu Kuang, Can Tu, Zhi-jie Ma, Jing-yao Pang, Yan-hui Wang, Qing-ce Zang, Ta-si Liu, Yan-ling Zhao, Xiao-he Xiao, Jia-bo Wang. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatinBiomedicine & Pharmacotherapy 2018; 99: 325 doi: 10.1016/j.biopha.2018.01.071
Letícia F Ramos, Caio M Silva, Camila C Pansa, Karen C M Moraes. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liverExpert Review of Gastroenterology & Hepatology 2021; 15(1): 25 doi: 10.1080/17474124.2020.1820321
Anastazia A. Kei, Theodosios D. Filippatos, Moses S. Elisaf. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemiaExpert Opinion on Drug Safety 2016; 15(4): 559 doi: 10.1517/14740338.2016.1157164